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Objective: Optic neuritis (ON) is an immune-mediated optic neuropathy associated with multiple immunemediated neurological conditions. Our aim was to characterize the clinical and diagnostic features of first or
initial episodes of ON associated with multiple sclerosis (MS)-associated (typical) and antibody-related (atypical)
ON.
Methods: Retrospective, single institution, medical record review. We analyzed demographic, clinical, laboratory,
and radiographic findings of 139 patients who presented with first episodes of MS-associated ON (MS-ON),
aquaporin 4 antibody–associated ON (AQP4-ON), and myelin oligodendrocyte glycoprotein antibody–associated
ON (MOG-ON) between January 2015 and October 2019 without preceding diagnosis. Simple hypothesis testing
assessed differences between groups were performed.
Results: Of 139 patients (109 [79 %] women; 29 [21 %] men; mean age 47 [SD, 14] years), 106 had MS-ON, 25
had AQP4-ON, and 8 had MOG-ON. Patients with MOG-ON had the highest recurrence rate (88 %) relative to
MS-ON (28 %) and AQP4-ON (56 %) patients (P < .001). Patients with AQP4-ON had the highest mean visual
functional system scores (4.3 [SD, 1.8]) relative to MS-ON (2.0 [SD, 1.9]) and MOG-ON patients (2.8 [SD, 2.0])
(P < .001).
Conclusion: Patients presenting with initial episodes of ON exhibit a range radiographic and laboratory feature
depending on the underlying associated disease. Understanding the variable characteristics of typical (MSassociated) and atypical (antibody-associated) ON may help physicians accurately diagnose and effectively treat
ON.

1. Introduction
Optic neuritis (ON) is an immune-mediated optic neuropathy with a
range of presentations and is associated with numerous conditions,
including infections, autoimmune disorders, and other diseases. Typical
ON presents as eye pain, impaired color vision, and monocular visual
loss that occurs over one week or less. The eye pain often worsens with
movement, and the onset typically coincides with visual acuity (VA)
changes.[1,2] ON can be the initial presenting symptom of various
immune-mediated neurological diseases.[3–6] In most cases, typical ON

has a well-known association with multiple sclerosis (MS). Atypical ON
is a severe form of the disease characterized by poor VA and outcomes.
Atypical ON may manifest as an autoimmune antibody disorder and is
mostly associated with neuromyelitis optica spectrum disorder
(NMOSD).[2] The novel discovery that auto-antibodies against
aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG)
can lead to ON has changed the clinical paradigm of this disorder.
Whereas acute episodes of ON associated with MS often self-resolve,
antibody-associated ON involving AQP4-IgG or MOG-IgG is more se
vere and may have a longer disease course [7,8].
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ON is often diagnosed based on clinical parameters, and magnetic
resonance imaging (MRI) of the brain and orbits with gadolinium
contrast can help to confirm the diagnosis. MRI of the brain can also be
used to assess the risk of subsequent development of MS, where the
affected optic nerve reveals abnormal enhancement on MRI orbit in the
majority of patients.[9,10] However, ON associated with MS, anti-AQP4
antibodies, and anti-MOG antibodies can have similar clinical pre
sentations. They can be challenging to differentiate at the onset of dis
ease, where serologic testing is required to distinguish these forms. The
long-term prognosis in MOG-ON is still controversial. There is no
registered prospective comparative study. Maybe, there are some dif
ferences between races.
This retrospective study aimed to characterize and compare the
clinical, radiographic, and laboratory features of ON associated with MS,
anti-AQP4 antibodies, and anti-MOG antibodies at the onset of disease
without preceding diagnosis. A thorough clinical definition outlining the
characteristics of different ON manifestations will help physicians
effectively diagnose and treat this variable disorder.

acuity (VA) at the time of presentation (rated from 0 to 6). Lower VFSS
scores indicate better VA, and higher VFSS scores indicate poor VA.
Patients with a history of ON who had alternative diagnoses such as
lupus, granulomatous optic neuropathies (e.g., sarcoidosis), or trau
matic, toxic, ischemic, infectious, and compressive optic neuropathies
were excluded. We also excluded patients who did not have a dedicated
orbital imaging, clinical follow-up, or who were not tested for anti-AQP4
and anti-MOG IgG antibodies. 87 patients were tested for AQP4-IgG and
only 25 tested positive. For the race comparison for VFSS, the overall
difference was significant (p = 0.0015) with pairwise comparisons
showing that Blacks have a significantly higher mean VFSS when
compared to Whites (supplementary table).
2.2. Statistical analysis
All continuous variables used means and standard deviations (SD),
while categorical variables used counts and column percentages. Uni
variate two-group comparisons used chi-square or Fisher exact tests (if
expected cell counts were < 5) for categorical variables and Wilcoxon
rank-sum tests for continuous variables. Nonparametric tests were
chosen when group sizes were small and when normality assumptions
were violated. Continuous data were compared between > 2 groups
using Kruskal-Wallis tests. Given the number of demographic, clinical,
radiological and spinal fluid characteristics being considered, the sta
tistical significance was set at a more conservative value of P < 0.01. Pvalues between 0.01 and 0.05 were considered as showing a trend. Post
hoc analyses used Benjamini-Hochberg adjustments to assess pairwise
comparisons of the three ON groups. All analyses were performed using
SAS 9.4 (SAS Institute Inc, Cary, NC).

2. Materials and methods
2.1. Method and data collection
This was a retrospective study of electronic health records that
included patients diagnosed with ON and who were treated in the
neurology and ophthalmology clinics at the Henry Ford Health System
(Detroit, MI) between January 2015 and mid-October 2019. This study
was approved by the Henry Ford Health System’s Institutional Review
Board. A natural language search of the electronic medical record sys
tem (Epic, Verona, WI) used the keywords “optic neuritis” (ICD-10-CM
Diagnosis Code G36.0) to identify patients. We identified 220 patients
with the diagnosis of ON. Clinical, demographic, radiographic, and
laboratory data, as well as treatment and symptoms recurrence were
recorded.
We included patients (N = 139) with a presentation consistent with a
first episode of clinical ON associated with MS (MS-ON), anti-AQP4
antibodies (AQP4-ON), and anti-MOG antibodies (MOG-ON).[11] We
excluded 35 patients who had optic neuropathy secondary to other
etiologies such as traumatic (N = 12), compressive (N = 6), ischemic (N
= 11), and toxic (N = 6). Patients with chronic relapsing inflammatory
optic neuritis (N = 6) who tested negative for both anti-AQP and
anti-MOG IgG were also excluded. Additionally, patients with sarcoid
osis associated ON (n = 5), and idiopathic ON (N = 35) who did not full
fill the diagnostic criteria for MS, AQP-4 and MOG were also excluded
from the study.
MS cases were confirmed based on McDonald’s 2010 revised criteria.
[12,13] A cell-based assay analyzed by cytometry was used for
anti-AQP4 and anti-MOG IgG surface antibody detection in serum.[13,
14] Samples were sent to the Mayo Clinic (Rochester, MN) for
interpretation.
Records indicating MRI of the brain and orbit with and without
gadolinium contrast performed at the time of symptom onset were
analyzed. All patients obtained a standardized imaging protocol with a
1.5 Tesla MRI scanner that had axial T2 weighted and/or fluidattenuated inversion recovery (FLAIR) sequences, coronal T2, or
FLAIR sequences of the whole brain and coronal sequences with or
without axial T2 fat suppressed (FS) sequences. Coronal and/or axial T1
weighted FS sequences were performed following gadolinium adminis
tration. Additionally, cerebrospinal fluid (CSF) studies such as white
blood cell count (WBC), CSF protein, CSF oligoclonal bands (O bands),
and CSF IgG index were documented and were analyzed. We also
analyzed patient treatment with pulse steroids, weaning oral predni
sone, and maintenance immunosuppressive therapy and symptom
recurrence, when present.
All patient records included calculated visual functional system
scores (VFSS) from the expanded disability status scale based on visual

3. Results
3.1. Patient characteristics
Patient demographic information and clinical characteristics by
diagnosis are in Table 1. Diagnostic study results such as MRI orbit data
and CSF laboratory results are in Table 2. Of the 139 patients included in
this analysis, 106 (76 %) had MS-ON, 25 (18 %) had AQP4-ON, and 8
(5.7 %) had MOG-ON. The mean (SD) age at diagnosis was 47 (14) years,
with no statistical difference in age of onset between the 3 groups. The
majority of patients were White (49 %) and were women (79 %).
Whereas 91/134 (68 %) of patients presented with unilateral ON, 43
(32 %) presented with bilateral ON. Although proportionately more
patients with AQP4-ON (46 %) had bilateral ON than patients with MSON (30 %) or MOG-ON (13 %), there was no significant difference across
groups (P = .163).
A total of 51/139 patients (37 %) had recurrent ON, with the highest
rate of recurrence within the MOG-ON group (88 %) relative to patients
in the AQP4-ON (56 %) and MOG-ON (28 %) groups (P < .001). VFSS
scores (rated from 0 to 6) measured at the onset of symptoms were
recorded for 98 patients, where the overall mean (SD) VFSS score was
2.7 (2.1). VFSS scores differed significantly between groups (P < .001),
with the highest mean (SD) score of 4.3 (1.8) for patients with AQP4-ON,
followed by 2.8 (2) for MOG-ON and 2.0 (1.9) for MS-ON patients.
All 8 patients in the MOG-ON group received high-dose pulsed
intravenous methylprednisolone (IVMP) treatment followed by an oral
steroid taper. A total of 20 patients (80 %) with AQP4-ON and 54 with
MS-ON (51 %) received IVMP treatment (P < .001), while 3 patients
with AQP4-ON received plasmapheresis for steroid-refractory ON. Only
101 health records included notation for steroid taper therapy, and the
proportions of patients receiving this therapy differed between groups
(P < .001).
3.2. Radiological and spinal fluid characteristics
All 139 patient records included MRI results (Table 2). Optic nerve
2
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Table 1
Demographic and descriptive clinical characteristics of patients with optic
neuritis.
a

Variable (N = 139)

Age in years, mean
(SD)
(N = 139)
Sex, No. ( %)
(N = 138)
female

Table 2
Radiological and spinal fluid characteristics of patients with optic neuritis.
a

b

Overall

MS-ON
(n =
106)

AQP4ON
(n = 25)

MOGON
(n = 8)

Pvalue

47 (14)

45
(13.9)

52
(14.9)

51 (8.6)

.084
.303

male
Race/ethnicity, No. (
%)
(N = 137)
Black
White
Other/Unknown
Side of ON, No. ( %)
(N = 134)
Unilateral
Bilateral
Recurrence, No. ( %)
(N = 139)
No
Yes
VFSS, mean (SD)
score
(N = 98)
IVMP, No. ( %)
(N = 139)
No
Yes
Unknown
Steroid taper, No. (
%)
(N = 101)
No
Yes
Unknown

109
(79)
29 (21)

83 (78)

21 (88)

5 (63)

23 (22)

3 (13)

3 (38)

45 (33)
67 (49)
25 (18)

33 (31)
49 (4)
24 (22)

12 (52)
10 (44)
1 (4)

0
8 (100)
0

91 (68)
43 (32)

71 (70)
31 (30)

13 (54)
11 (46)

7 (88)
1 (13)

.020

0.163

Variable (N = 139)

MS-ON
(n =
106)

AQP4ON
(n = 25)

MOGON
(n = 8)

Positive MRI intra-orbital
T2 signal changes, No. (
%)
Positive MRI orbit
enhancement, No. ( %)
Presence of MRI
intracanalicular
segment involvement,
No. ( %)
Presence of MRI orbit
optic chiasm
involvement, No. ( %)
CSF O bands, No. ( %)
(N = 74)

48 (35)

24 (23)

18 (72)

6 (75)

<
.001

49 (35)

24 (23)

18 (72)

7 (88)

22 (16)

12 (11)

10 (40)

0

<
.001
.001

5 (4)

0

5 (20)

0

<
.001

MS-ON
n = 50
33 (45)
41 (55)

31 (62)
19 (38)

Overall

MS-ON
n = 48

CSF IgG index, mean (SD)
(N = 73)

0.9
(0.6)
Overall

1.1
(0.5)
MS-ON
n = 47

CSF WBC, leukocytes/
mm3, mean (SD)
(N = 75)

9.7
(14.4)

12
(16.4)

AQP4ON n =
20
8.0
(11.1)

MOGON n =
7
0
7 (100
%)
MOGON n =
8
0.8
(1.1)
MOGON n =
8
2.1
(2.5)

<
.001

positive
negative

AQP4ON n =
17
2 (12)
15 (88)

Overall

MS-ON
n = 47

CSF protein, mg/dL, mean
(SD)
(N = 74)

40.8
(32.9)

39
(29.6)

AQP4ON n =
19
41
(44.2)

MOGON n =
8
48
(20.0)

<.001
88 (63)
51 (37)
2.7
(2.1)

76 (72)
30 (28)
2.0 (1.9)

11 (44)
14 (56)
4.3 (1.8)

1 (13)
7 (88)
2.8
(2.0)

< .001

<.001
56 (40)
82 (59)
1 (1)

52 (49)
54 (51)
0

4 (16)
20 (80)
1 (4)

0
8 (100)
0
<.001

35 (35)
65 (64)
1 (1)

34 (49)
36 (51)
0

1 (4)
21 (91)
1 (4)

0
8 (100)
0

b

Total

AQP4ON n =
17
0.5 (0.4)

Pvalue

<
.001

.023

.048

Abbreviations: AQP4-ON, aquaporin 4–associated ON; CSF, cerebrospinal
fluid; MOG-ON, myelin oligodendrocyte glycoprotein-associated ON; MRI,
magnetic resonance imaging; MS-ON, multiple sclerosis-associated ON; O band,
oligoclonal band; ON, optic neuritis; WBC, white blood cells
a
Some patient records did not contain information for certain variables
b
Kruskal-Wallis test for continuous data and chi-square or Fisher’s exact for
categorical data

Abbreviations: AQP4-ON, aquaporin 4–associated ON; IVMP, intravenous
methylprednisolone; MS-ON, multiple sclerosis–associated ON; MOG-ON,
myelin oligodendrocyte glycoprotein–associated ON; ON, optic neuritis; VFSS,
visual function system score
a
Some patient records did not contain information for certain variables
b
Kruskal-Wallis test for continuous data and chi-square or Fisher exact test for
categorical, data

3.3. Post hoc analysis

intra-orbital segment T2 signal abnormalities on MRI orbit scan were
reported in 48 (35 %) patients. Of these patients, signal changes were
seen in 6 MOG-ON (75 %), 18 AQP4-ON (72 %), and 24 MS-ON (23 %)
patients (P < 0.001). A total of 49 (35 %) patients demonstrated optic
nerve intra-orbital segment enhancement on MRI orbit. While 7 of 8
patients (88 %) with MOG-ON had orbit enhancement, 18 (72 %) AQP4ON and 24 (23 %) MS-ON patients (P < .001) showed this result. Optic
nerve intracanalicular segment involvement was seen in 22 patients (16
%), including 10 (40 %) patients in the AQP4-ON group and 12 (11 %) in
the MS-ON group; however, it was not observed in patients with MOGON (P = .001). Optic chiasm enhancement was seen only in 5 AQP4-ON
patients (4 % of all patients; 20 % of AQP4-ON group; P < .001).
A total of 74 patients had CSF O band analysis performed, where 33
(45 %) had positive and 41 (55 %) had negative results. While none of
the 7 patients with MOG-ON who were tested had positive CSF O bands,
31/50 (62 %) of the tested MS-ON patients and only 2/17 of the tested
AQP4-ON patients had positive O bands (P < 0.001). The highest mean
(SD) CSF IgG index was seen in the MS-ON group at 1.1 (0.5) compared
to 0.8 (1.1) for the MOG-ON and 0.5 (0.4) for the AQP4-ON groups (P <
0.001). The mean CSF WBC and protein levels showed difference trends
(P < 0.05) between the 3 groups (Table 2).

Table 3 gives the adjusted P values from post hoc analysis comparing
each pair of the significant variables from Tables 1 and 2. A BenjaminiHochberg adjustment was applied to all raw P values to account for the
inflation of the type I error rate inherent to pairwise comparisons. There
were significantly more recurrences in the MOG-ON group compared to
the MS-ON group (7/8 [87 %] vs 30/106 [28.3 %]; adjusted P = 0.004).
Average VFSS was significantly higher in the AQP4-ON group than in the
MS-ON group.
4. Discussion
This single-institution retrospective study assessed the diversity of
clinical presentations and treatments of patients who presented with the
first or initial episode of 3 different types of ON: MS-ON, AQP4-ON, and
MOG-ON. In our study group, most of the patients were women, which is
in accordance with other studies that have shown a female preponder
ance of 90 % in AQP4-ON patients, greater than the MS-ON group.[16,
17] In a study of 531 ON cases in Japan, the male to female ratio was
1:1.22. But our patient population showed a higher proportion of
women compared to the Japanese cohort,[18] with the highest pro
portion of female patients in the AQP4-ON group (84 %) followed by the
MOG-ON group (51 %). The median age of onset for AQP4-ON has been
3
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results differ from the Ramanathan study26 and may reflect a higher
overall number of MS-ON and AQP4-ON patients in our cohort and the
relatively lower number of MOG-ON patients in our group. However,
despite the small number of MOG-ON patients in our group, a higher
percentage of recurrence was seen in this group than in the AQP4-ON
and MS-ON groups.
In our study group, only 61 % of patients received high-dose pulsed
IVMP for ON treatment, mostly in the AQP4-ON and MOG-ON groups.
Almost half of the MS-ON patients were not treated with IVMP given
normal (20/20) or low normal VA (20/20–20/30) scores and subtle or
no changes seen on orbital MRI. A higher proportion of patients in the
AQP4-ON and MOG-ON groups received oral prednisone taper after
IVMP. These results indicate that steroid taper might be needed in these
two groups, given severe and atypical ON features with low VA and poor
visual recovery after IVMP treatment.
ON can be diagnosed based on the clinical and ophthalmologic
evaluation. However, an MRI of the brain and orbits with gadolinium
contrast is recommended for most patients with suspected ON to
determine its clinical association with immune-mediated neurological
conditions, which is needed for a better long-term treatment plan that
will affect the clinical outcome.[27–29] Features on the MRI orbit can be
conducive for distinguishing typical ON from atypical ON.
Optic nerve lesions seen in patients with MS are typically short
segments and are anteriorly located (intra-orbital).30 Posterior optic
pathway involvement (intracranial segment, optic tract, and optic
chiasm), bilateral involvement, and enhancement are rare and should
raise suspicion for atypical ON.[26,30] The orbital MRI features of our
patients were similar to other published reports. Our study showed that
only 23 % of MS-ON cases had a radiological correlation with the orbital
MRI, somewhat different from what was reported in Ramanathan et al.,
which showed 62 % of MS patients (8/13) having optic nerve T2
hyperintensity. The authors also reported that these changes were either
mild (5/13) or moderate (2/13), and that only 1/13 patients demon
strated significant T2 signal changes, with a moderate degree of T2
hyperintense changes seen in both AQP4-ON and MOG-ON groups.
However, these results should be interpreted with caution because of the
small sample size of their MS cohort [26].
One of our study’s showed the intracanalicular segment involvement
of the optic nerve in 40 % of AQP4-ON and 11 % of the MS-ON groups.
The optic nerve has 4 portions moving from anterior to posterior:
intraocular, intra-orbital, intracanalicular, and intracranial. While the
anterior visual pathway is usually affected in typical ON (MS-associ
ated), the posterior visual pathway is more often involved in atypical ON
(eg, AQP4-ON)16; however, the intracanalicular segment lies in between
the anterior and the posterior pathways, making involvement in this
region somewhat difficult to interpret. Although it is commonly seen in
AQP4-ON, a small proportion of MS-ON patients can show the intra
canalicular segment’s involvement: thus, abnormalities in this region
should be interpreted with caution. One should be skeptical in auto
matically attributing this finding to atypical ON, AQP4-IgG and MOGIgG antibody testing should be performed for this subgroup. Intra
canalicular lesion is not so rare in MOG-ON. Furthermore, correctly
evaluating intracanalicuar lesions on orbital MRI images is not easy, and
the interpretation may differ between physicians.
Although CSF studies are not considered a necessity in the diagnostic
workup for ON, they can help assess some atypical cases.[31] About 90
% of MS patients may have CSF O bands, which rarely present in
anti-AQP4 and anti-MOG disorders,[18] where they are seen in about
20 % of patients with AQP4-ON.[18] The presence of CSF O bands also
supports the dissemination in time criteria for MS that is incorporated in
the revised 2017 McDonald’s criteria.[12,13] Our finding that 62 % of
patients with MS-ON had positive CSF O bands aligns with previous
findings.[18] Interestingly, the mean CSF IgG index was elevated in both
the MS-ON and MOG-ON groups. We also looked at the mean CSF pro
tein level and WBC count, and the results showed difference trends. This
finding is different from other published reports, where higher CSF WBC

Table 3
Adjusted P values from post hoc pairwise comparisons.
Variable

Comparison

MS-ON vs
AQP4-ON

MS-ON
vs MOGOM

AQP4-ON
vs MOGON

Recurrence
VFSS
IVMP
Steroid taper
MRI intraorbit T2
signal
MRI orbit enhancement

Yes vs No
Yes vs No
Yes vs No
Yes vs No
Positive vs
Negative
Positive vs
Negative
Yes vs No

0.073
< 0.001
0.011
< 0.001
0.003

0.004
0.352
0.015
0.015
0.008

0.101
0.097
0.550
0.733
0.626

< 0.001

0.001

0.643

0.005

0.597

0.143

Yes vs No

< 0.001

N/A2

0.302

Yes/
Nonspecific vs
No
Positive vs
Negative
Positive vs
Negative

< 0.001

0.017

0.999

< 0.001

0.005

0.999

< 0.001

0.022

0.834

MRI intracanalicular
segment involvement
MRI orbit optic chiasm
involvement
MRI brain lesions
consistent with MS
CSF O bands
CSF IgG index

Abbreviations: AQP4-ON, aquaporin 4–associated ON; CSF, cerebrospinal
fluid; MOG-ON, myelin oligodendrocyte glycoprotein-associated ON; MRI,
magnetic resonance imaging; MS-ON, multiple sclerosis-associated ON; O band,
oligoclonal band; ON, optic neuritis; WBC, white blood cells
1There are no Other/Unknown or Black patients in the MOG-ON group
2There are no patients with MRI orbit optic chiasm involvement in the MS-ON or
MOG-ON groups

reported to be 35–45 years,[14,15] whereas for MOG-ON, onset occurs
at 31–37 years, with a female-to-male ratio of 2:1–3:1.[17,19] However,
the median age for our study population was older than in those reports.
Recent studies estimate that the annual incidence of ON is about 2.57
per 100,000 person-years, which is consistent with several previous
population-based studies.[20–22] In our study population, White pa
tients were more frequently affected than other ethnicities overall: while
we observed a higher number of African American patients within the
AQP4-ON group, all of the 8 patients with MOG-ON were White. How
ever, these differences in our study were not significant, and our findings
support our patient cohort’s geographic location.
In our study, patients with AQP4-ON presented with severe visual
deficits with high VFSS scores (mean 4.3), indicating lower VA: these
observations align with what was seen in a Japanese cohort, where the
VA was poor in the AQP4 IgG-positive patients, with 53 % of patients
showing VA restricted to finger counting or worse. In an 8-year retro
spective descriptive study of patients with ON, 50/150 (33 %) were
diagnosed with the anti-AQP4 disorder, and a high number of these
patients (74 %) presented with worse than 20/200 VA.[23] Although
optic nerve susceptibility in patients with AQP4-ON is multifaceted, the
leading hypothesis for severe visual loss is that a highly vulnerable
isoform of the autoantibody targeting AQP4 is expressed preferentially
in astrocytes located in the optic nerve, which initiates the intense in
flammatory demyelinating cascade. [24] Another interesting finding of
our study is the significantly higher VFSS (p = 0.00015) in African
American patients compared to Caucasians. In a cross sectional study
comparing the visual outcome in patients with ON associated with
MOG-IgG, AQP4-IgG and MS included 39 % African American patients.
This study showed a lower thickness of macular ganglion call+ inner
plexiform layer in AQP4-ON group compared to MS-ON and MOG-ON
groups with poor visual outcome. Age, sex and race did not alter these
findings. [25] A study by Ramanathan et al.[26] assessed a cohort of 50
patients with ON associated with AQP4 antibodies, MOG antibodies, and
MS and reported that bilateral ON was more common in MOG-ON and
AQP4-ON patients (84 % and 82 %) than in MS-ON (23 %) patients. We
observed that bilaterality was more common in the AQP4-ON group (46
%) than in patients with MS-ON or MOG-ON (30.4 % and 12.5 %). Our
4
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cell counts (> 50 cells) in AQP4-ON patients than in MS-ON patients
have been observed [32,33].
In our study, almost all patients received maintenance immuno
modulatory / immunosuppressive medications, including glatiramer
acetate (40.7 %), rituximab (11 %), azathioprine (6 %), methotrexate
(1.7 %), teriflunomide (3.4 %), natalizumab (7.6 %), interferon-beta
(25.4 %), fingolimod (7.6 %), dimethyl fumarate (16.9 %), mycophe
nolate mofetil (7.6 %), and cyclophosphamide (0.7 %). Treatment de
tails are listed in the Supplementary Table. Multiple patients were
switched from one immunotherapy to another either due to side effects
or disease recurrence. MS patients on low or intermediate efficacy drugs
were switched to high efficacy treatment due to the disease’s recurrence.
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ever, this study provides important demographic, clinical, and radio
graphic distinctions of patients with 3 distinct forms of ON: AQP4-ON,
MOG-ON, and MS-ON. Early recognition of these conditions may affect
patient clinical outcomes, as patients with anti-AQP4 and anti-MOG
associated ON may present with high VFSS score at the onset of dis
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